NCT01965119View on ClinicalTrials.gov

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 15, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

September 18, 2018

Conditions
Relapsed or Refractory Hodgkin LymphomaPrimary Mediastinal Large B-cell Lymphoma
Interventions
DRUG

Ruxolitinib

20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.

Trial Locations (7)

Unknown

Busan University Hospital, Busan

Dong-A University, Busan

Kosin University Gospel Hospital, Busan

Chung-Ang University Hospital, Seoul

138-736

Asan Medical Center, Seoul

139-706

Korean Cancer Center Hospital, Seoul

220-701

Wonju Severance Christian Hospital, Wŏnju

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT01965119 - Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter